Fundraising Fox
Advaxis
Monmouth Junction, US · Delaware corporation · 1 known investors
Find your way into Advaxis
Each arrow is one introduction. Sign up to fill in the first one.
99 people can intro you to Igor
Ask Panna Sharma to introduce you to Igor Gitelman
You →Panna · together at Cancer Genetics, Inc. →Igor
Sign up to find every way you can get introduced to Advaxis
- Your email: who you already know at Advaxis, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Advaxis team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
IG
Igor GitelmanExecutiveIgor Gitelman has held financial leadership roles including Interim Chief Financial Officer at Ayala Pharmaceuticals and Chief Financial Officer at Accu Reference Medical Lab. He holds a CPA license, an MBA degree, and SAP Certified Application Associate credential, with over 20 years of experience in accounting, finance, and audit.
AG
Andres GutierrezExecutive
KB
Kenneth BerlinExecutive
JR
John RothmanExecutive
MJ
Mark J. RosenblumExecutive
RA
Roni AppelNamed on SEC filing
Board
DS
SK
Samir KhleifBoard director
RB
Richard BermanBoard director
JP
James PattonBoard director
TM
Thomas McKearnBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$17.3M disclosed across 4 rounds · 2012–2023
▶$433.8KraisedNov 2023 · 3 investors · BiotechnologyRule 506(b)
▶$433.8KraisedNov 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andres GutierrezExecutive Officer
- Igor GitelmanExecutive Officer
- Pini OrbachDirector
- Murray GoldbergDirector
- Vered Bisker-LeibDirector
- Yuval CabillyDirector
- Bridget MartellDirector
- Roy GolanExecutive Officer
- Robert SpiegelDirector
- David SidranskyDirector
- Roni AppelDirector
- Ken A. BerlinDirector, Executive Officer
- Offering amount
- $433.8K
- Amount sold
- $433.8K
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.8MraisedFeb 2022 · 6 investors · BiotechnologyRule 506(b)
▶$4.8MraisedFeb 2022 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth BerlinExecutive Officer, Director
- Samir KhleifDirector
- Igor GitelmanExecutive Officer
- Roni AppelDirector
- James PattonDirector
- Andres GutierrezExecutive Officer
- David SidranskyDirector
- Richard BermanDirector
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- Minimum investment
- $380K
- Finders' fees
- $295K
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.1MraisedApr 2021 · 2 investors · BiotechnologyRule 506(b)
▶$11.1MraisedApr 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Samir KhleifDirector
- Richard BermanDirector
- Igor GitelmanDirector
- Andres GutierrezExecutive Officer
- Roni AppelDirector
- Kenneth BerlinExecutive Officer, Director
- David SidranskyDirector
- James PattonDirector
- Offering amount
- $11.1M
- Amount sold
- $11.1M
- Minimum investment
- $3M
- Finders' fees
- $1.1M
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedFeb 2012 · 12 investors · BiotechnologyRule 506(b)
▶$1MraisedFeb 2012 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas MooreExecutive Officer, Director
- Richard BermanDirector
- John RothmanExecutive Officer
- Thomas McKearnDirector
- Roni A. AppelDirector
- James PattonDirector
- Mark J. RosenblumExecutive Officer
- Amount sold
- $1M
- Sales commissions
- $73.3K
- Placement agents
- Rodman & Renshaw, LLC
- First sale
- Jan 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Advaxis's investors?
- Advaxis's investors include Israel Biotech Fund.
- How much funding has Advaxis raised?
- Advaxis has disclosed $17.3M raised across 4 rounds.
- Where is Advaxis headquartered?
- Advaxis is headquartered in Monmouth Junction, US.